title: Epstein-Barr virus-related lymphoproliferative disease after allogeneic bone marrow transplantation for severe aplastic anemia complicated by the syndrome of inappropriate secretion of antidiuretic hormone.
authors.forename: M
authors.initials: M
authors.lastname: Ostronoff
authors.forename: F
authors.initials: F
authors.lastname: Ostronoff
authors.forename: R
authors.initials: R
authors.lastname: Florêncio
authors.forename: A P Souto
authors.initials: AP
authors.lastname: Maior
authors.forename: A
authors.initials: A
authors.lastname: Sucupira
authors.forename: R
authors.initials: R
authors.lastname: Calixto
authors.forename: M C
authors.initials: MC
authors.lastname: Domingues
authors.forename: C
authors.initials: C
authors.lastname: Tagliari
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005260:Female; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000150:complications* / Q000188:drug therapy; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology*; D000069283:Rituximab; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D004317:Doxorubicin